Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1%Compared With Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Participants With Moderate to Severe Acne
SKIN The Journal of Cutaneous Medicine · 10.03.2026 · 10 (2) · s764
DOI: 10.25251/7gk6kp53 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.03.2026. Verfasst von Zoe Draelos und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The American Academy of Dermatology guidelines for treating mild to severe acne strongly recommend a combination of topical retinoids, benzoyl peroxide (BPO) and/or topical or oral antibiotics. Topical clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatment. CAB showed superior efficacy to component dyads and vehicle, with good tolerability and safety in a phase 2 and two phase 3 clinical trials of participants with moderate to severe acne. Results from a second phase 2 trial of CAB gel comparing its efficacy/safety in a head-to-head trial versus commercially available adapalene 0.3%/BPO 2.5% (ADAP/BPO) gel are reported here.
Methods
In a phase 2, double-blind, 12-week clinical trial (NCT04892706), participants with moderate to severe acne aged ≥12 years were randomized (2:2:1:1) to once-daily CAB, ADAP/BPO, or 1 of 2 vehicle gels (combined for analysis). Co-primary endpoints included percentage of participants achieving treatment success (≥2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin) and least squares (LS) mean absolute change from baseline in inflammatory and noninflammatory lesion counts at week 12. Secondary endpoints included LS mean percent change from baseline in lesion counts at week 12. Treatment-emergent adverse events (TEAEs) were also evaluated. Co-primary endpoints were further analyzed by subgroups defined by participant age (
Zitieren
APA
Draelos, Z., Baldwin, H., Bhatia, N., Eichenfield, L., Wroblewski, K., Eichenfield, D. Z., & Kircik, L. (2026). Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1%Compared With Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Participants With Moderate to Severe Acne. SKIN The Journal of Cutaneous Medicine, 10(2), s764. https://doi.org/10.25251/7gk6kp53
Vancouver
Draelos Z, Baldwin H, Bhatia N, Eichenfield L, Wroblewski K, Eichenfield DZ, et al. Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1%Compared With Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Participants With Moderate to Severe Acne. SKIN The Journal of Cutaneous Medicine. 2026;10(2):s764. doi:10.25251/7gk6kp53
BibTeX
@article{Draelos2026,
author = {Draelos, Zoe and Baldwin, Hilary and Bhatia, Neal and Eichenfield, Lawrence and Wroblewski, Karol and Eichenfield, Dawn Z. and Kircik, Leon},
title = {Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1%Compared With Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Participants With Moderate to Severe Acne},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {s764},
doi = {10.25251/7gk6kp53}
}
EUVIMED